Lundbeck Q3 2019 Financial Results
Lundbeck continues to execute on its Expand and Invest to Grow
strategy through the acquisition of Alder BioPharmaceuticals
大
Maintaining the former
Alder site in Bothell, just
outside of Seattle,
Washington in the U.S.
Integration progressing
rapidly
大 Main focus on
biopharmaceutical product
development and supply
Financing and closing
complete
Eptinezumab
*
U.S. PDUFA action date: 21 Feb.
2020
Planned fillings: Canada (Q1.20), EU
(by end-2020)
Preparing the path for China, Japan
and emerging markets
Market Access
*
*
Initiating phase IIIb study to
facilitate EU market access
Building insights and relationships
to prepare global markets
Expanding eptinezumab
*
Drive Treat & Prevent study
*
Define and pursue future
indications
14
Landbec⭑View entire presentation